Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C.

Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El-Kafrawy S, Mikhail N, Magder LS, Afdhal NH, Strickland GT.

J Hepatol. 2007 Apr;46(4):620-7. Epub 2007 Jan 24.

PMID:
17316875
2.

Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection.

Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ, Sampaio JP, Medina-Pestana JO, Lanzoni VP, Silva AE, Ferraz ML.

J Viral Hepat. 2008 Sep;15(9):666-74. doi: 10.1111/j.1365-2893.2008.00992.x. Epub 2008 May 14.

PMID:
18482283
3.

YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection.

Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, Silva AE.

Scand J Gastroenterol. 2010 May;45(5):615-22. doi: 10.3109/00365521003637203.

PMID:
20163287
4.

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.

Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC; HALT-C Trial Group.

Hepatology. 2008 Mar;47(3):789-98. doi: 10.1002/hep.22099.

5.

Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C.

Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA.

Am J Gastroenterol. 2008 Apr;103(4):928-36. doi: 10.1111/j.1572-0241.2007.01761.x. Epub 2008 Mar 25.

PMID:
18371145
6.

Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.

Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T.

World J Gastroenterol. 2005 Jan 28;11(4):476-81.

7.

Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.

Lee CK, Perez-Atayde AR, Mitchell PD, Raza R, Afdhal NH, Jonas MM.

J Pediatr. 2013 Oct;163(4):1058-64.e2. doi: 10.1016/j.jpeds.2013.04.044. Epub 2013 Jun 5.

PMID:
23759423
8.

The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.

Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N.

J Gastroenterol Hepatol. 2009 Apr;24(4):564-8.

PMID:
19378390
9.

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH.

J Hepatol. 2005 Jul;43(1):78-84. Epub 2005 Apr 25.

PMID:
15894397
10.

Predictive accuracy of serum hyaluronic acid as a non-invasive marker of fibrosis in a cohort of multi-transfused Egyptian children with β-thalassaemia major.

El-Shabrawi MH, Zein El Abedin MY, Omar N, Kamal NM, Elmakarem SA, Khattab S, El-Sayed HM, El-Hennawy A, Ali AS.

Arab J Gastroenterol. 2012 Jun;13(2):45-8. doi: 10.1016/j.ajg.2012.06.006. Epub 2012 Jul 11.

PMID:
22980590
11.

Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C.

Patel K, Nelson DR, Rockey DC, Afdhal NH, Smith KM, Oh E, Hettinger K, Vallée M, Dev A, Smith-Riggs M, McHutchison JG.

Clin Gastroenterol Hepatol. 2008 Feb;6(2):242-7. doi: 10.1016/j.cgh.2007.11.009. Epub 2008 Jan 9.

PMID:
18187364
12.

Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C.

Deghady A, Abdou A, El-Neanaey WA, Diab I.

Genet Test Mol Biomarkers. 2012 Jun;16(6):531-5. doi: 10.1089/gtmb.2011.0098. Epub 2012 Feb 21.

PMID:
22352690
13.
14.

Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children.

Nassef YE, Shady MM, Galal EM, Hamed MA.

Mem Inst Oswaldo Cruz. 2013 Nov;108(7):887-93. doi: 10.1590/0074-0276130139.

15.

[Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease].

Kim SM, Sohn JH, Kim TY, Roh YW, Eun CS, Jeon YC, Han DS, Oh YH.

Korean J Hepatol. 2009 Dec;15(4):454-63. doi: 10.3350/kjhep.2009.15.4.454. Korean.

16.

Serum hyaluronic acid and laminin as biomarkers in liver fibrosis.

Parsian H, Rahimipour A, Nouri M, Somi MH, Qujeq D, Fard MK, Agcheli K.

J Gastrointestin Liver Dis. 2010 Jun;19(2):169-74. Retraction in: Acalovschi M. J Gastrointestin Liver Dis. 2012 Mar;21(1):118.

17.

Serum YKL-40 is increased in patients with hepatic fibrosis.

Johansen JS, Christoffersen P, Møller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F.

J Hepatol. 2000 Jun;32(6):911-20.

PMID:
10898311
18.

Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease.

Testa E, Malfatti F, Milazzo S, Cordiviola C, Cotellessa T, Marabotto E, Giannini E, Ceppa P, Mamone M, Risso D, Testa R.

Liver Int. 2006 May;26(4):439-44.

PMID:
16629647
19.

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE.

Hepatology. 2005 Jun;41(6):1376-82.

PMID:
15915455
20.

Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group.

McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ.

J Gastroenterol Hepatol. 2000 Aug;15(8):945-51.

PMID:
11022838

Supplemental Content

Support Center